Please login to the form below

Not currently logged in
Email:
Password:

gene therapy

This page shows the latest gene therapy news and features for those working in and with pharma, biotech and healthcare.

Pfizer hedges bets on gene therapy deal

Pfizer hedges bets on gene therapy deal

Pfizer had looked like the most obvious buyer for Spark, as the two companies are co-developing a gene therapy treatment for haemophilia B. ... Vivet Therapeutics’ lead candidate is VTX-801, a gene therapy for Wilson disease, a devastating rare, chronic

Latest news

More from news
Approximately 51 fully matching, plus 158 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Lonza has worked with 150 cell and gene therapy developers and each project has required a different approach, Hong added. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said Hong.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... Sangamo CEO Sandy Macrae (below) attempted to convince investors that the results were a step on the path to an in vivo gene-editing therapy that is

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Pivotal data from two studies in the severe inherited blood

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    In Ciba-Geigy/Sandoz, the FTC was concerned that the merger could impair the development of gene therapy, a market that the FTC forecast to be worth US$45bn within 20 years ... Although the parties divested one of the gene therapy programmes to Aventis,

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Pfizer also has a considerable stake in one of the most exciting emerging areas of innovation, cell and gene therapy. ... It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.

More from intelligence
Approximately 4 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics